Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Moderna (MRNA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report), Incyte (INCY – Research Report) and Moderna (MRNA – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Roche Holding AG (RHHVF)
In a report released today, Luisa Hector from Berenberg Bank maintained a Hold rating on Roche Holding AG, with a price target of CHF340.00. The company’s shares closed last Tuesday at $487.10.
According to TipRanks.com, Hector is a 4-star analyst with an average return of
Roche Holding AG has an analyst consensus of Moderate Buy, with a price target consensus of $448.06, which is a -8.6% downside from current levels. In a report issued on February 9, J.P. Morgan also maintained a Hold rating on the stock with a CHF350.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Incyte (INCY)
Barclays analyst Etzer Darout maintained a Buy rating on Incyte today and set a price target of $117.00. The company’s shares closed last Tuesday at $101.16.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $109.13, representing a 7.3% upside. In a report issued on February 5, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $135.00 price target.
Moderna (MRNA)
In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Moderna, with a price target of $41.00. The company’s shares closed last Tuesday at $43.93, close to its 52-week low of $29.25.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
Currently, the analyst consensus on Moderna is a Hold with an average price target of $33.63, implying a -20.5% downside from current levels. In a report issued on February 2, Citi also maintained a Hold rating on the stock with a $28.00 price target.
